Detection of Metastases from Gastrointestinal Neuroendocrine Tumors: Prospective Comparison of 18 F-TOCA PET,Triple-Phase CT,and PET/CT

Abstract

The purpose of the investigation was to assess positron emission tomography (PET), computed tomography (CT) and the image fusion of PET and CT (PET/CT) in the detection of metastases from gastrointestinal neuroendocrine tumors. In a prospective study, thirty-one patients were consecutively examined using a state-of-the-art PET/CT. PET was performed with a carbohydrated F-18-labeled somatostatin receptor ligand (Gluc-Lys([¹⁸F]FP-TOCA) from the base of the skull to the proximal thigh using a Pico-3D PET scanner. CT was performed with a noncontrast low-dose CT (LD-CT) and a venous-dominant contrast-enhanced CT (VD-CT) from the base of the skull to the proximal thigh and a hepatic arterial-dominant contrast-enhanced CT (AD-CT) from the epigastric region using a 16-slice CT. The data sets from PET and CT (LD-CT and VD-CT) were fused automatically. To assess a relative sensitivity of each imaging modality, the total number of metastases by summing the number of metastases depicted for each patient by the highest sensitive modality was used as reference standard. PET, LD-CT, AD-CT, VD-CT, PET/LD-CT and PET/VD-CT showed a lesion-by-lesion based overall detection rate for liver metastases (n=858) of 90.8% (P<0.001), 29.4% (P<0.001), 45.5% (P<0.001), 73.9% (P<0.001), 91.5% (P<0.001) and 100%. PET, LD-CT, VD-CT, PET/LD-CT and PET/VD-CT showed an overall detection rate for lymph node metastases (n=193) of 93.8% (P<0.001), 25.4% (P<0.001), 64.8% (P<0.001), 93.8% (P<0.001) and 100% and for osseous metastases (n=567) of 98.6% (P<0.005), 40.7% (P<0.001), 40.7% (P<0.001), 100% and 100%. Furthermore, PET revealed 2 (22.2%) of 9 intrapulmonal lesions seen on LD-CT, VD-CT, PET/LD-CT and PET/VD-CT. PET as single modality revealed most liver, lymph node and osseous metastases. The combination of molecular/metabolic with anatomical/morphological information improves the diagnostic accuracy for the detection of metastases in comparison to any single imaging modality. LD-CT cannot replace VD-CT in the detection of liver and lymph node metastases, but was equal in the detection of osseous metastases and identifying of pulmonary lesions.

Keywords

Gastrointestinal neuroendocrine tumors Somatostatin receptor imaging Whole-body imaging Positron emission tomography (PET)TOCA PET Computed tomography (CT)PET/CT PET-CT

References

Reubi

J.C.

Kvols

L.K.

Waser

Nagomey

D.M.

Heitz

P.U.

Charboneau

J.W.

Reading

C.C.

Moertel

Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 50, 569–577 (1990).

Kaltsas

Rockall

Papadogias

Reznek

Grossman

A.B.

Recent advances in radiological und radionuclide imaging and therapy of neuroendocrine tumours. Eur. J. Endocrinol. 151, 15–27 (2004).

Capella

Heitz

P.U.

Hoefler

Solcia

Kloeppel

Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Digestion 55, 11–23 (1994).

Kloeppel

Heitz

P.U.

Capella

Solcia

Pathology and nomenClature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. World J. Surg. 20, 132–141 (1996).

Kulke

M.H.

Mayer

Carcinoid tumors. N. Engl. J. Med. 340, 858–868 (1999).

McDermott

E.W.

Guduric

Brennan

M.F.

Prognostic variables in patients with gastrointestinal carcinoid tumours. Br. J. Surg. 81, 1007–1009 (1994).

Janson

E.T.

Holmberg

Stridsberg

Eriksson

Theodorsson

Wilander

Oberg

Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann. Oncol. 8, 685–690 (1997).

Sutliff

V.E.

Doppman

J.L.

Gibril

Venzon

D.J.

Serrano

Jensen

Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J. Clin. Oncol. 15, 2420–2431 (1997).

Weber

H.C.

Venzon

D.J.

Lin

J.T.

Fishbein

V.A.

Orbuch

Strader

D.B.

Gibril

Metz

D.C.

Fraker

D.L.

Norton

J.A.

Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: A prospective long-term study. Gastroenterology 108, 1637–1649 (1995).

10.

Stinner

Kisker

Zielke

Rothmund M Surgical management for carcinoid tumors of small bowel, appendix, colon and rectum. World J. Surg. 20, 183–188 (1996).

11.

Debray

M.P.

Geoffroy

Laissy

J.P.

Lebtahi

Silbermann-Hoffman

Henry-Feugeas

M.C.

Cadiot

Mignon

Schouman-Claeys

Imaging appearance of metastases from neuroendocrine tumours of the pancreas. Br. J. Radiol. 74, 1065–1070 (2001).

12.

Kvols

L.K.

Moertel

C.G.

O'Connel

M.J.

Schutt

A.J.

Rubin

Hahn

R.G.

Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue. N. Engl. J. Med. 315, 663–666 (1986).

13.

Lamberts

S.W.J.

Krenning

E.P.

Reubi

J.C.

The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 12, 430–482 (1991).

14.

Krenning

E.P.

Kwekkeboom

D.J.

Bakker

W.H.

Breeman

W.A.

Kooij

P.P.

Oei

H.Y.

van Hagen

Posteman

P.T.

de Jong

Reubi

J.C.

Somatostatin receptor scintigraphy with [¹¹¹ In-DTPA-D-Phe¹]- and [¹²³ I-Tyr³]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20, 716–731 (1993).

15.

Gibril

Reynolds

J.C.

Doppman

J.L.

Chen

C.C.

Venzon

D.J.

Termanini

Weber

H.C.

Stewart

C.A.

Jensen

R.T.

Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann. Intern. Med. 125, 26–34 (1996).

16.

Schillaci

Scopinaro

Angeletti

Tavolaro

Danieli

Annibale

Gualdi

Delle Fave

SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors. J. Nucl. Med. 37, 1452–1456 (1996).

17.

Lebtahi

Cadiot

Sarda

Daou

Faraggi

Petegnief

Mignon

le Guludec

Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J. Nucl. Med. 38, 853–858 (1997).

18.

Schillaci

Spanu

Scopinaro

Falchi

Danieli

Marongiu

Pisu

Madeddu

Delle Fave

Madeddu

Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. J. Nucl. Med. 44, 359–368 (2003).

19.

van der Lely

A.J.

de Herder

W.W.

Krenning

E.P.

Kwekkeboom

D.J.

Octreoscan radioreceptor imaging. Endocrine 20, 307–311 (2003).

20.

Behr

T.M.

Behe

Becker

Diagnostic applications of radiolabeled peptides in nuclear endocrinology. Q. J. Nucl. Med. 43, 268–280 (1999).

21.

Meisetschlaeger

Poethko

Stahl

Wolf

Scheidhauer

Schottelius

Herz

Wester

H.J.

Schwaiger

Gluc-Lys([¹⁸F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [¹¹¹ In]DTPA-octreotide. J. Nucl. Med. 47, 566–573 (2006).

22.

Wester

H.-J.

Schottelius

Scheidhauer

Meisetschlaeger

Herz

Rau

F.C.

Reubi

J.C.

Schwaiger

PET imaging of somatostatin receptors: Design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide. Eur. J. Nucl. Med. Mol. Imaging 30, 117–122 (2003).

23.

Kwekkeboom

D.J.

Krenning

E.P.

Bakker

W.H.

Oei

H.Y.

Kooij

P.P.M.

Lamberts

S.W.J.

Somatostatin analogue scintigraphy in carcinoid tumours. Eur. J. Nucl. Med. 20, 283–292 (1993).

24.

Seemann

M.D.

Meisetschlaeger

Gaa

Rummeny

E.J.

Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI. Eur. J. Med. Res. 11, 58–65 (2006).

25.

Kluetz

P.G.

Meltzer

C.C.

Villemagne

V.L.

Kinahan

P.E.

Chander

Martinelli

M.A.

Townsend

D.W.

Combined PET/CT imaging in oncology: Impact on patient management. Clin. Pos. Imag. 3, 223–230 (2000).

26.

Even-Sapir

Keidar

Sachs

Engel

Bettman

Gaitini

Guralnik

Werbin

Iosilevsky

Israel

The new technology of combined transmission and emission tomography in evaluation of endocrine neoplams. J. Nucl. Med. 42, 998–1004 (2001).

27.

Lardinois

Weder

Hany

T.F.

Kamel

E.M.

Korom

Seifert

von Schulthess

G.K.

Steinert

H.C.

Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N. Engl. J. Med. 348, 2500–2507 (2003).

28.

Seemann

M.D.

Gaa

Images in cardiovascular medicine. Cardiac metastasis: Visualization with positron emission tomography, computed tomography, magnetic resonance imaging, positron emission tomography/computed tomography, and positron emission tomography/magnetic resonance imaging. Circulation 112, e329–330 (2005).

29.

Kwekkeboom

Krenning

E.P.

De Jong

Peptide receptor imaging and therapy. J. Nucl. Med. 41, 1704–1713 (2000).

30.

Patel

Y.C.

Somatostatin and its receptor family. Front. Neuroendocrinol. 20, 157–198 (1999).

31.

Seemann

M.D.

Human PET/CT scanners: Feasibility for oncological in vivo imaging in mice. Eur. J. Med. Res. 9, 468–472 (2004).

32.

Bader

T.R.

Semelka

R.C.

Chiu

V.C.

Armao

D.M.

Woosley

J.T.

MRI of carcinoid tumors: Spectrum of appearances in the gastrointestinal tract and liver. J. Magn. Reson. Imaging 14, 261–269 (2001).

33.

Paulson

E.K.

McDermott

V.G.

Keogan

M.T.

DeLong

D.M.

Frederick

M.G.

Nelson

R.C.

Carcinoid metastases to the liver: Role of triple-phase helical CT. Radiology 206, 143–150 (1998).

34.

Van Hoe

Gryspeerdt

Marchal

Baert

A.L.

Mertens

Helical CT for the preoperative localization of islet cell tumors of the pancreas: Value of arterial and parenchymal phase images. A.J.R. 165, 1437–1439 (1995).

35.

Stafford-Johnson

D.B.

Francis

I.R.

Eckhauser

F.E.

Knol

J.A.

Chang

A.E.

Dual-phase helical CT of nonfunctioning islet cell tumors. J. Comput. Assist. Tomogr. 22, 335–339 (1998).

36.

Ichikawa

Peterson

M.S.

Federle

M.P.

Baron

R.L.

Haradome

Kawamori

Nawano

Araki

Islet cell tumor of the pancreas: Biphasic CT versus MR imaging in the tumor detection. Radiology 216, 163–171 (2000).

37.

Oliver

J.H.

3rd Baron

R.L.

Federle

M.P.

Jones

B.C.

Sheng

Hypervascular liver metastases: Do unenhanced and hepatic arterial phase CT images affect tumor detection? Radiology 205, 709–715 (1997).

38.

Dromain

de Baere

Lumbroso

Caillet

Laplanche

Boige

Ducreux

Duvillard

Elias

Schlumberger

Sigal

Baudin

Detection of liver metastases from endocrine tumors: A prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J. Clin. Oncol. 23, 70–78 (2005).

39.

Zimmer

Ziegler

Bader

Fett

Hamm

Riecken

E.O.

Wiedenmann

Localization of neuroendocrine tumors of the upper gastrointestinal tract. Gut 35, 471–475 (1994).

40.

Bollen

E.C.

Goei

van't Hof-Grootenboer

B.E.

Versteege

C.W.

Engelshove

H.A.

Lamers

R.J.

Interobserver variability and accuracy of computed tomographic assessment of nodal status in lung cancer. Ann. Thorac. Surg. 58, 158–162 (1994).

41.

Gibril

Doppman

J.L.

Reynolds

J.C.

Chen

C.C.

Sutliff

V.E.

Serrano

Venzon

D.J.

Jensen

R.T.

Bone metastases in patients with gastrinomas: A prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. J. Clin. Oncol. 16, 1040–1053 (1998).